source
- Atea’s hepatitis C combo matches Gilead’s Epclusa in phase 3 trialBoston-based biotech Atea Pharmaceuticals reported that its once-daily hepatitis C combination of bemnifosbuvir and ruzasvir performed on par with Gilead's Epclusa in a pivotal phase 3 study. The…
- FDA finds Capricor's Duchenne stem cell therapy failed to meet Phase 3 goals, contradicting company claimsThe U.S. Food and Drug Administration announced that the stem cell treatment from Capricor Therapeutics did not achieve the primary objectives in its Phase 3 trial for Duchenne muscular dystrophy.…